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Background: Patients with end-stage renal disease (ESRD) have high rates of hospitalization for cardiovascular
(CV) events and short-term mortality after the initiation of hemodialysis (HD) therapy. To improve outcomes,
it is important to identify predictive laboratorymarkers. We investigatedwhether the serum bone-speciﬁc alka-
line phosphatase (BAP) level at the initiation of HD therapy for ESRD was associated with adverse events.
Methods: Thiswas a retrospective cohort study of 47 ESRDoutpatientswhowere referred to our clinic for HD. The
serum BAP level was measured within 1 month after the initiation of HD. Patients were divided into high-BAP
and low-BAP groups according to the median serum BAP level (24.6 U/L). The impact of the serum BAP level
on CV events (coronary artery disease, peripheral arterial disease, cerebrovascular disease, other CV events in-
cluding aortic dissection, and mortality) was investigated.
Results: During a median follow-up period of 72 months, CV events occurred in 14 patients (29.8%). Kaplan–Meier
analysis showed that the disease-free and overall survival rates were lower in the high-BAP group than in the low-
BAP group (p = 0.003 and p = 0.037, respectively, log-rank test). After adjustment for age, sex, and other con-
founding factors, Cox proportional hazards analysis found that the high-BAP group had a 5.9-fold higher rate of
CV events than the low-BAP group (hazard ratio: 5.89; 95% conﬁdence interval: 1.184–29.309; p = 0.030).
Conclusions: The serum BAP level at the initiation of HD therapy for ESRD is a useful non-invasive biomarker for
predicting CV events.
© 2014The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Patients undergoing dialysis have signiﬁcantly higher rates of hospi-
talization for cardiovascular (CV), cerebrovascular, and peripheral arte-
rial disease (PAD) than those not undergoing dialysis [1–5]. It is
therefore important to identify predictive factors for CV events in pa-
tients with end-stage renal disease (ESRD) who are starting dialysis
[6,7]. The identiﬁcation of associations between laboratory markers at
the initiation of hemodialysis (HD) and CV events enables risk stratiﬁca-
tion of patients with ESRD.gy, Tokyo Women's Medical
, Japan. Tel.: +81 3 3353-8111;
ima).
rk.
and Ltd. This is an open access articleESRD is associatedwith disorders of bonemetabolism such as chron-
ic kidney disease (CKD)–mineral and bone disorder (MBD) [8]. CKD–
MBD is associated with the development of vascular calciﬁcation,
which contributes to the morbidity and mortality of dialysis patients
[9,10]. The abnormalities of mineral and bone metabolism begin prior
to the initiation of dialysis, and there is a signiﬁcant progression of vas-
cular calciﬁcation in HD patients compared with CKD stage 4 patients
[11,12]. These ﬁndings suggest that the preceding abnormalities ofmin-
eral and bonemetabolismmay be associated with CV events in new di-
alysis patients.
Bone-speciﬁc alkaline phosphatase (BAP) is a laboratory marker
used to assess mineral and bone metabolism in patients with ESRD
[13]. The Kidney Disease: Improving Global Outcomes position state-
ment indicates that the improvement of non-invasive diagnosis of
CKD–MBD and associated CV complications is urgently needed to im-
prove outcomes in patients with CKD [8]. However, the relationshipunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Baseline demographic characteristics according to the serum BAP level.
Lower BAP Higher BAP
(BAP b 24.6) (BAP ≥ 24.6) p value
Numbers 23 24
Age (years) 52 ± 15 59 ± 18 0.126
Male (%) 87.0 58.3 0.028
Body mass index (kg/m2) 23.2 ± 3.3 21.8 ± 3.3 0.192
Blood pressure (mm Hg)
Systolic 141 ± 22 136 ± 18 0.445
Diastolic 83 ± 13 79 ± 12 0.296
Comorbidity (%)
Diabetes mellitus 30.4 45.8 0.278
History of CAD 13.0 20.8 0.477
Laboratory values
Albumin (g/dL) 4.0 ± 0.4 3.9 ± 0.4 0.369
Hemoglobin (g/dL) 9.0 ± 1.2 9.6 ± 1.2 0.126
eGFR (mL/min per 1.73 m2) 5.5 ± 1.9 7.4 ± 3.1 0.011
ALP (U/L) 211.1 ± 76.6 287.1 ± 93.2 0.004
Serum calcium (mg/dL) 8.1 ± 0.9 8.0 ± 0.5 0.851
Serum phosphate (mg/dL) 6.0 ± 1.3 5.2 ± 1.7 0.086
Whole PTH (pg/dL) 99.8 ± 56.1 173.2 ± 124.9 0.017
Magnesium (mg/dL) 2.4 ± 0.5 2.2 ± 0.6 0.311
Uremic acid (mg/dL) 7.6 ± 1.8 7.3 ± 1.6 0.559
Presence of AoAC (%) 26.1 41.7 0.260
Medications (%)
ACE inhibitor or ARB use 82.6 78.3 0.710
β-Blocker use 30.4 29.2 0.924
Anti-HPT drug use 91.3 62.5 0.020
Statin use 13 17.4 0.681
Values aremean (±SD) or percentage. BAP, bone-speciﬁc alkaline phosphatase; CAD, cor-
onary artery disease; eGFR, estimated glomerular ﬁltration rate based on theModiﬁcation
of Diet in Renal Disease formula; ALP, alkaline phosphatase; PTH, parathyroid hormone;
AoAC, aortic arch calciﬁcation; ACE, angiotensin-converting enzyme; ARB, angiotensin II
receptor blocker; HPT, hyperparathyroid.
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mains unclear.
The purpose of this retrospective cohort study was to elucidate the
value of the serum BAP level at the initiation of HD therapy, which is a
direct marker of bone turnover, for predicting adverse CV events in
ESRD patients.
2. Methods
2.1. Patients
Eighty-eight patients with ESRDwere referred to the Dialysis Unit of
Shinjuku Ishikawa Clinic (Shinjuku-ku, Tokyo, Japan) within 1 month
after startingHDbetween 2005 and 2008. The 72 patients who received
three dialysis sessions per week were reviewed. Patients with malig-
nancy (n = 2), infectious or inﬂammatory disease (n = 2), chronic
liver disease (n = 1), lower extremity amputation for PAD (n = 2), or
no serum BAP level measured within 1 month (n= 18) were excluded.
The remaining 47 patients were included in the analysis of the relation-
ship between the serum BAP level at the initiation of HD and CV events.
The estimated glomerular ﬁltration rate (eGFR) was calculated using
the Cockcroft–Gault equation [14]. Patient characteristics, co-morbid
conditions, and medications were recorded from the medical notes
and referral form. This retrospective study protocol was approved by
the institutional review board of Tokyo Women's Medical University.
2.2. Blood sampling
Blood was taken before dialysis to measure the circulating levels of
various markers, including calcium (Ca) and phosphorus. Serum Ca
levels were adjusted using the formula [Ca + (4-albumin)]. Serum
whole parathyroid hormone (PTH) (1–84) level and BAP level were
measured using an IRMA kit (DS Pharma Biomedical, Osaka, Japan)
and an EIA kit (Alkphase-B, Metra Biosystems, Mountain View, CA,
USA), respectively. The serum BAP level was measured within
1 month after the initiation of HD.
2.3. Assessment of aortic arch calciﬁcation (AoAC)
The presence or absence of AoAC on the ﬁrst posteroanterior chest
X-ray after starting HD was assessed. AoAC was deﬁned as any visible
calciﬁcation, including small spots of calciﬁcation, a single thin area of
calciﬁcation at the aortic knob, one or more areas of thick calciﬁcation,
or circular calciﬁcation at the aortic knob [15].
2.4. Deﬁnitions of CV events
CV morbidity and mortality were recorded. CV morbidity included
coronary artery disease (CAD), PAD, stroke, intracranial hemorrhage,
and other CV events requiring hospitalization. CAD was deﬁned as
acute coronary syndrome or percutaneous coronary intervention for
stable or unstable angina. PAD was deﬁned as angiographically veriﬁed
stenosis of the peripheral arteries with cold extremities, numbness, in-
termittent claudication, or pain at rest. Stroke and intracranial hemor-
rhage were diagnosed by imaging studies or neurological criteria.
Other CV events included aortic dissection. Disease-free survival (DFS)
was deﬁned as the time from enrollment to the CV event or death,
whichever occurred ﬁrst. Overall survival (OS) was deﬁned as the
time from enrollment to death from any cause. Follow-up data were
available for all patients to May 31, 2013.
2.5. Statistical analysis
All variableswere tested for a normal distribution using the Shapiro–
Wilk test. The data are presented asmean±SD, or asmedian and range.
The baseline clinical data were compared between groups using theStudent's t-test or Mann–Whitney U test. Categorical variables were
compared using a chi-square analysis. Because of the lack of a recom-
mended cutoff value for the serum BAP level and its non-normal distri-
bution, patients were dichotomized into a low-BAP group (serum BAP
level lower than the median) and a high-BAP group (serum BAP level
equal to or higher than themedian). The cumulative event-free survival
was calculated using the Kaplan–Meier analysis. Differences in DFS and
OS between groups were assessed using the log-rank test. The predic-
tors of DFS and OS were identiﬁed using the Cox proportional hazards
model. The hazard ratio (HR)with 95% conﬁdence interval (CI) was cal-
culated for each factor by Cox univariate analysis. Coxmultivariate anal-
yses for DFS and OS were adjusted for age, sex, and the factors found to
be signiﬁcantly associated with outcome on univariate analysis. As the
serum alkaline phosphatase (ALP) level has colinearity with the serum
BAP level, the ALP level was excluded from the analysis. All p values
are two-sided. Differences were considered to be statistically signiﬁcant
at p b 0.05. Statistical analyseswere performed using IBMSPSS software
version 19.0 (IBM, Somers, NY, USA).
3. Results
3.1. Patient characteristics
The baseline characteristics of patients are shown in Table 1. The
study group included 47 patients (33 men, 14 women) with a mean
age of 56 ± 17 years. The median follow-up period was 72 months
(range, 16–96 months). The median serum BAP level was 24.6 U/L
(range, 10.8–84.2 U/L). The high-BAP group had a lower proportion of
male patients than the low-BAP group. The serum ALP level, whole
PTH level, and eGFR were higher in the high-BAP group than in the
low-BAP group. The use of anti-hyperparathyroid agents, including
phosphate binders and vitamin D therapy, was less frequent in the
high-BAP group than in the low-BAP group. AoAC and a history of
CAD tended to be more frequent in the high-BAP group than in the
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index, systolic or diastolic blood pressure, prevalence of diabetes
mellitus, albumin level, hemoglobin level, calcium level, phosphorus
level, magnesium level, uremic acid level, use of antihypertensive
agents, use of β-blockers, or use of statins between the two groups at
baseline.3.2. Patient outcomes
During the follow-up period, 11 CV events and 8 deaths occurred in
14 patients (Table 2). Among the patients who died, two had coronary
artery events, one had an intracranial hemorrhage, and two had periph-
eral arterial events. The most common cause of CV events was CAD
(45.5%), followed by stroke or intracranial hemorrhage (27.3%). Eight
patients (17.0%) died by the end of May 2013.3.3. Impact of the serum BAP level on CV events and mortality
Kaplan–Meier curves for DFS and OS, stratiﬁed according to theme-
dian serum BAP level, are shown in Fig. 1. DFS was worse in the high-
BAP group than in the low-BAP group (p = 0.003, log-rank test). CV
events tended to occur in the early years after the initiation of HD.
OS was also worse in the high-BAP group than in the low-BAP group
(p = 0.037, log-rank test). Death tended to occur several years after
the initiation of HD. The difference between the time of the ﬁrst non-
fatal CV event and the time of death was 3.7± 1.7 years. Receiver oper-
ating characteristic curve analysis showed that the optimal cutoff value
of the serumBAP level for predicting CV events was 24.2 U/L. This cutoff
value had high sensitivity (92.9%) andmoderate speciﬁcity (63.6%). The
optimal cutoff value of the serum BAP level for predicting overall death
was 30.9 U/L. This cutoff value had moderate sensitivity (62.5%) and
moderate speciﬁcity (76.9%).Fig. 1.Kaplan–Meier analyses of (A) disease-free survival and (B) overall survival. Patients
were divided into two groups according to the median serum BAP level. The disease-free
and overall survival rates were lower in the high-BAP group than in the low-BAP group.
Patients who underwent renal transplantation were censored at the time of transplanta-
tion for both Kaplan–Meier analyses. For disease-free survival, patients were censored at
the end of the follow-up period if they were alive without CV events. For overall survival,
patients were censored at the end of the follow-up period if they were alive.3.4. Univariate and multivariate analyses for CV events and mortality
Univariate andmultivariate Cox proportional hazards analyses were
performed to identify the factors predicting CV events (Table 3). Univar-
iate analyses found that age, eGFR, and a high serum BAP level were as-
sociatedwith CV events.Multivariate analysis found that patientswith a
high serum BAP level had a 5.9-fold increased risk of CV events com-
pared with patients with a low serum BAP level (HR: 5.89; 95% CI:
1.184–29.309; p = 0.030). After adjustment for age, sex, and history
of CAD, OS tended to be worse in the high-BAP group than in the low-
BAP group (HR: 3.24; 95% CI: 0.314–33.405; p= 0.324), but this differ-
ence was not signiﬁcant.Table 2
Summary of outcomes for analysis of DFS and OS.
Case Gender Age DFS OS
1 F 72 ACS Death
2 F 75 ACS
3 M 80 ACS
4 M 71 Underwent PCI
5 M 59 Underwent PCI Death
6 M 52 Stroke
7 M 45 Stroke
8 M 80 Intracranial hemorrhage Death
9 M 71 PAD Death
10 F 72 PAD Death
11 M 29 Aortic dissection (Stanford A)
12 M 72 Cardiac sudden death Death
13 M 73 Death (malignancy) Death
14 F 54 Death (malignancy) Death
DFS, disease-free survival; OS, overall survival; ACS, acute coronary syndrome; PCI, percu-
taneous coronary intervention; PAD, peripheral arterial disease.4. Discussion
The results of this study demonstrate that: (1) a high serum BAP
level at the initiation of HD was associated with CV events; (2) a high
serum BAP level was an independent risk factor for CV events; (3) CV
events were generally observed in the early years after the initiation
of HD; and (4) CADwas the leading cause of CV events. The clariﬁcation
of the prognostic values of non-invasive measurements at the initiation
of HD is urgently needed to improve outcomes in patients with ESRD.
Data regarding the impact of the serum BAP level at the initiation of
HD for ESRD on clinical outcomes are currently lacking. The results of
this study provide information on the value of the serum BAP level for
predicting CV events in patients starting dialysis.
In this study, we showed that the serumBAP level at the initiation of
HD is an important predictive factor for CV events. Our results are con-
sistent with those of previous studies [16,17], which reported that a
high serumBAP levelwas a signiﬁcant predictor of all-cause death in pa-
tients receiving HD. However, previous studies measured the serum
BAP level during themaintenance phase of HD therapy, and theﬁndings
cannot be extrapolated to ESRDpatients startingHD. Furthermore,mor-
bidity and mortality rates have been still high during the early years of
dialysis [18]. These ﬁndings suggest that the measurement of the
serum BAP level should be evaluated at the initiation of dialysis therapy
to improve the clinical outcomes for patients starting dialysis.
Table 3
Univariate and multivariate analyses for DFS and OS.
DFS OS
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age (years) 1.050 1.004–1.096 0.034 1.044 0.991–1.101 0.107 1.093 1.011–1.181 0.025 1.085 1.005–1.170 0.036
Male gender 0.925 0.290–2.953 0.896 2.307 0.577–9.546 0.249 0.629 0.150–2.643 0.527 1.816 0.405–8.138 0.436
Diabetes mellitus 1.644 0.576–4.691 0.353 3.189 0.721–14.111 0.126
History of CAD 1.385 0.386–4.975 0.617 4.486 1.000–20.121 0.050 3.261 0.641–16.594 0.155
Presence of AoAC 2.699 0.937–7.774 0.066 2.947 0.699–12.427 0.141
Use of anti-HPT drugs 0.776 0.243–2.477 0.668 0.510 0.122–2.141 0.358
eGFR 1.376 1.135–1.668 0.001 1.195 0.966–1.478 0.101 1.127 0.897–1.416 0.306
Ca × P (mg2/dL2) 0.952 0.899–1.008 0.089 0.973 0.916–1.034 0.379
Whole PTH (pg/mL) 0.998 0.992–1.004 0.542 0.994 0.983–1.005 0.261
BAP (≥24.6 U/L) 6.916 1.545–30.965 0.011 5.891 1.184–29.309 0.030 6.854 0.841–55.862 0.072 3.238 0.314–33.405 0.324
DFS, disease-free survival; OS, overall survival; CAD, coronary artery disease; AoAC, aortic arch calciﬁcation;HPT, hyperparathyroid; eGFR, estimated glomerularﬁltration rate based on the
Modiﬁcation of Diet in Renal Disease formula; Ca, calcium; P, phosphate; PTH, parathyroid hormone; BAP, bone-speciﬁc alkaline phosphatase.
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group than in the low-BAP group, especially during the early years after
initiation of HD. These results may have important clinical implications
for patients starting HD. First, it has been reported that the risk of ad-
verse events is particularly high during the ﬁrst 2 years after the initia-
tion of dialysis, and that patients with CAD have a higher risk of death
during this time than those without CAD [19,20]. In the present study,
a history of CAD tended to be associated with death. Second, patients
who undergo coronary revascularization procedures after the initiation
of renal replacement therapy have poor long-term survival [21,22].
Third, the 3-year mortality rate after limb revascularization procedures
is signiﬁcantly higher in patients with ESRD than those without ESRD
[23]. Finally, Sozio et al. reported that cerebrovascular events occurred
10 timesmore frequently in patients starting dialysis than in the general
population, and that these events had a signiﬁcant risk of mortality [4].
In the present study, CV events were non-fatal in the early years after
the initiation of HD, but the longer-term mortality rate tended to be
higher in the high-BAP group than in the low-BAP group, despite the
better prognosis of JapaneseHDpatients relative to those in other coun-
tries [24]. The avoidance of revascularization procedures after CV events
within a few years after the initiation of HDmay result in a reduced risk
of overall mortality.
The results of the present study show that CAD was the leading
cause of CV events after the initiation of HD. It has been reported that
patients with ESRD are already at a very high risk of coronary artery ste-
nosis at the initiation of renal replacement therapy [25]. Furthermore,
Kono et al. reported that coronary plaque morphology in patients with
HD is correlated with mineral disorders [26]. Our results strengthen
the association between the degree of disordered mineral metabolism
at the initiation of HD for ESRD and CV events.
BAP is a useful biomarker that reﬂects both bone turnover and vascu-
lar calciﬁcation [13,27]. Vascular calciﬁcation is one of the major compli-
cations of CKD–MBD [7]. In vitro studies found that vascular smooth
muscle cells derived from the vascularmedia can be stimulated to under-
go phenotypic transformation into bone-forming osteoblast-like cells [13,
28], and that such transformation increases the expression of BAP [29].
Orita et al. reported a correlation between the serum BAP level and the
area of calciﬁed lesions in an animal model [30]. Furthermore, arterial
media calciﬁcation is common in HD patients and is a strong prognostic
indicator of all-cause and CV mortality [31,32]. In the present study, vas-
cular calciﬁcation on chest X-ray tended to be more frequent in the
high-BAP group than in the low-BAP group. In addition, it has been re-
ported that starting dialysis accelerates medial vascular calciﬁcation by
triggering smooth muscle cell apoptosis [33]. These ﬁndings suggest
that the initiation of dialysis may promote vascular calciﬁcation and
lead to CV events independently of the serum BAP level. All the patients
in this study received HD, and future studies should evaluate the impact
of an elevated serum BAP level with or without starting HD on CV events.Our results show that intervention for CKD–MBD in stage 5D renal
disease might be too late. It has been reported that an elevated serum
BAP level in patients with advanced stages of CKD is a risk factor for
CV events [34], and it is important to lower the serum BAP level before
dialysis. Recent clinical studies reported that the administration of vita-
min D analogs in CKD stages 3–4 and dialysis patients reduced the
serum BAP level [35,36]. Further studies are needed to determine
whether early intervention to lower the serum BAP level prior to dialy-
sis can decrease the rate of CV events.
5. Study limitations
Several limitations of our study should be discussed. First, there was
an inherent limitation in the retrospective cohort study design. The
study was conducted at a single center, and the sample size was small.
Second, we measured the serum BAP level at a single time point, which
did not allow us to evaluate the effects of changes in serum BAP level
after therapeutic interventions. Finally, we did not perform bone biop-
sies, and therefore cannot conﬁrm a direct relationship between the
serum BAP level and bone status in our population. It has previously
been reported that the serum BAP level reﬂects bone histomorphometry
ﬁndings, and Urena et al. found that a high serum BAP level predicted
histological ﬁndings indicating high-turnover bone disease [13,37].
6. Conclusions
The results of this study show that a high serum BAP level at the ini-
tiation of dialysis is an independent predictor of CV events. Starting the
management of mineral and bone disorders in an earlier CKD stagemay
reduce the frequency of adverse CV events after the initiation of HD
therapy.
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